Litcius/Paper detail

Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration

Fabian Frontzek, Loïc Renaud, Ulrich Dührsen, Viola Poeschel, Sophie Bernard, Loïc Chartier, Nicolas Ketterer, Christian Récher, Olivier Fitoussi, Gerhard Held, Olivier Casasnovas, Corinne Haïoun, Nicolas Mounier, Hervé Tilly, Franck Morschhauser, Steven Le Gouill, Imke E. Karsten, Gerben Duns, Christian Steidl, David W. Scott, Wolfgang Hiddemann, Andreas Rosenwald, German Ott, Thierry Jo Molina, Georg Lenz, Marita Ziepert, Bettina Altmann, Catherine Thiéblemont, Norbert Schmitz

2024Leukemia12 citationsDOI

Topics & Concepts

MedicineInternal medicineClinical trialOncologyTransplantationClinical endpointPrimary central nervous system lymphomaPhases of clinical researchDiffuse large B-cell lymphomaLymphomaSurgeryCNS Lymphoma Diagnosis and TreatmentLymphoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia research
Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration | Litcius